Market Overview - The Hong Kong stock market experienced a decline, ending a three-day rally since 2026, with all three major indices closing lower [1][2] - The Hang Seng Index fell by 0.94%, the Hang Seng China Enterprises Index dropped by 1.14%, and the Hang Seng Technology Index decreased by 1.49% [2] Sector Performance - Technology and automotive stocks underperformed, contributing to the overall market decline, while sectors such as innovative pharmaceuticals, non-ferrous metals, and coal stocks saw gains [2][4] - Notable declines in technology stocks included Tencent Music down over 5%, Alibaba down over 3%, and NIO, Xpeng, and Li Auto all closing lower [4][5] - The financial sector also faced weakness, particularly among brokerage stocks, with significant drops including CMB International down over 6% and Guotai Junan down over 5% [6][7] Regulatory Impact - The National Market Supervision Administration and the Cyberspace Administration of China issued new regulations for live-streaming e-commerce, aimed at enhancing industry oversight and protecting consumer rights [4] - Predictions indicate a potential 7% decline in China's automotive market sales in 2026, marking the first annual negative growth since 2020 [4] Innovative Pharmaceuticals - The innovative pharmaceutical sector showed resilience, with stocks like Rongchang Bio surging by 12.93% and other companies like Kangfang Bio and WuXi Biologics also posting significant gains [8][9] - Research indicates a positive shift in the CRO and CDMO industries, with expectations for improved investment conditions and demand recovery in the coming years [8] Coal and Non-Ferrous Metals - Certain coal and non-ferrous metal stocks performed well, with Nanshan Aluminum rising over 10% and other coal stocks like Lianhe Energy and Shougang Resources also seeing gains [10][11] - Research from GF Securities suggests that the coal industry's demand structure is optimizing, with a projected 5% growth in coal demand from the chemical sector [10]

Core Viewpoint - Guangfa Securities plans to raise approximately HKD 61 billion through a share placement and convertible bonds, with a share price set at HKD 18.15, which has led to a short-term decline in stock prices for both H-shares and A-shares [3][4]. Group 1: Financing Details - The company intends to issue 219 million shares at HKD 18.15 each, aiming to raise about HKD 39.75 billion [3]. - Additionally, Guangfa Securities plans to issue zero-coupon convertible bonds with a conversion price of HKD 19.82, expected to raise around HKD 21.5 billion, bringing the total fundraising to approximately HKD 61 billion [3][4]. Group 2: Market Reaction - Following the announcement, Guangfa Securities' H-shares dropped over 5%, falling below HKD 19, while A-shares decreased by 2.61%, closing at CNY 23.16 [3]. - Market analysts suggest that while the current sentiment in A-shares and H-shares is positive, the dilution of existing shareholders' equity due to the placement may lead to short-term bearish sentiment [3][4]. Group 3: Company Performance - Guangfa Securities reported a revenue of CNY 26.164 billion for the first nine months of 2025, marking a year-on-year increase of over 41% [4]. - The net profit for the same period was CNY 10.934 billion, reflecting a nearly 62% year-on-year growth, while the net profit excluding non-recurring items reached CNY 10.711 billion, up over 65% [4].

Market Overview - The Hong Kong stock market experienced its first decline of the year on January 7, with the Hang Seng Index closing at 26,458.95 points, down 251.50 points, a decrease of 0.94% [1][2]. - The Hang Seng Tech Index also fell, closing at 5,738.52 points, down 86.74 points, a decline of 1.49% [2]. Sector Performance - The pharmaceutical and biotechnology sector saw significant gains, with Rongchang Biologics (HK09995) rising over 12%, and other companies like Kailaiying (HK06821) and Tigermed (HK03347) increasing by over 8% [5]. - Rongchang Biologics announced positive clinical trial data for its PD-1/VEGF bispecific antibody RC148, which showed promising efficacy and safety for treating non-small cell lung cancer [5]. - Kangfang Biologics received approval for an important update on its PD-1/VEGF bispecific antibody, indicating significant clinical benefits in treating advanced non-small cell lung cancer [7]. Investment Trends - Southbound funds continued to significantly increase their holdings in Hong Kong stocks, with a net purchase exceeding 9.1 billion HKD by the end of the trading day [8]. - Research from CICC suggests that the Hong Kong stock market is entering a recovery phase, driven by a weaker US dollar and improved domestic liquidity, with a positive outlook for the first half of 2026 [12]. - Guotai Junan Securities anticipates a second round of valuation recovery and performance resurgence in the Hong Kong market in 2026, recommending focus on technology, healthcare, and consumer sectors [12]. Analyst Ratings - Credit Lyonnais maintained a "Outperform" rating for WuXi AppTec, raising the target price to 143.4 HKD, citing expected growth from outsourcing demand and reduced policy uncertainty [10].

Core Viewpoint - Guangfa Securities (01776.HK) announced the issuance of its fifth phase of short-term corporate bonds aimed at professional investors, with a coupon rate of 1.64% [1] Group 1: Bond Details - The bond, referred to as "25 Guangfa D7" with bond code 524303, will pay interest and principal on January 9, 2026, for the period from June 12, 2025, to January 8, 2026 [1] - The total amount payable for each unit (face value of 1,000 yuan) of the "25 Guangfa D7" bond, including tax, is 1,009.480547 yuan [1]

Group 1 - The core point of the article is that GF Securities (01776) announced the issuance of a short-term corporate bond aimed at professional investors, specifically the fifth phase of the bond, named "25 GF D7" [1] - The bond has a coupon rate of 1.64% and will pay interest and principal on January 9, 2026, for the period from June 12, 2025, to January 8, 2026 [1] - The total amount payable for each unit (face value of 1,000 yuan) of the "25 GF D7" bond, including tax, is 1,009.480547 yuan [1]

Core Viewpoint - Guangfa Securities (01776) announced the issuance of its fifth phase of short-term corporate bonds aimed at professional investors, with a coupon rate of 1.64% [1] Group 1: Bond Details - The bond, referred to as "25 Guangfa D7" with bond code 524303, will pay interest and principal on January 9, 2026, covering the period from June 12, 2025, to January 8, 2026 [1] - The total amount payable for each unit (face value of 1,000 yuan) of "25 Guangfa D7" will be 1,009.480547 yuan, including tax [1] - The payment date and bond delisting date is set for January 9, 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 GF SECURITIES CO., LTD. 廣發証券股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1776） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，廣發証券股份有限公司（「本公司」）在深圳 證券交易所網站( http://www.szse.cn )刊發的《廣發証券股份有限公司2025年面向專 業投資者公開發行短期公司債券（第五期）兌付兌息及摘牌公告》。茲載列如下， 僅供參閱。 承董事會命 廣發証券股份有限公司 林傳輝 董事長 中國，廣州 2026年1月7日 於本公告日期，本公司董事會成員包括執行董事林傳輝先生、秦力先生、孫曉燕 女士及肖雪生先生；非執行董事李秀林先生、尚書志先生及郭敬誼先生；獨立非 執行董事梁碩玲女士、黎文靖先生、張闖先生及王大樹先生。 债券代码：524303 债券简称：25 广发 ...

债券代码：524303 债券简称：25 广发 D7 广发证券股份有限公司 一、本期债券基本情况 1、债券名称：广发证券股份有限公司 2025 年面向专业投资者公开发行短期 公司债券（第五期） 2、债券简称及代码：本期债券简称为"25 广发 D7"，债券代码为"524303"。 3、债券发行批准机关及文号：中国证券监督管理委员会证监许可〔2025〕 818 号文。 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 广发证券股份有限公司 2025 年面向专业投资者公开发行短期公司债券（第 五期）（债券简称："25 广发 D7"，债券代码：524303，以下简称"本期债券"） 将于 2026 年 1 月 9 日支付 2025 年 6 月 12 日至 2026 年 1 月 8 日期间的利息及 本期债券的本金。为确保本次兑付兑息工作的顺利进行，现将有关事宜公告如下： 4、发行期限、规模和利率：本期债券发行期限为 211 天，发行规模为 50 亿 元，票面利率为 1.64%。 5、起息日：本期债券的起息日为 2025 年 6 月 12 日。 6、付息日：本期债券的 ...

Market Overview - The Hong Kong stock market experienced a downward trend, with the Hang Seng Index closing down 0.94% at 26,458.95 points and a total turnover of HKD 2,761.34 million [1] - The Hang Seng China Enterprises Index fell by 1.14% to 9,138.75 points, while the Hang Seng Tech Index decreased by 1.49% to 5,738.52 points [1] - Zheshang International noted that the fundamentals of the Hong Kong market remain weak, with a decline in the funding environment, while Goldman Sachs maintains an "overweight" rating on Chinese A-shares and H-shares, citing attractive risk-reward ratios [1] Blue Chip Performance - WuXi Biologics (02269) led blue-chip stocks, rising 5.92% to HKD 36.12, contributing 11.87 points to the Hang Seng Index [2] - Other notable blue-chip performers included Innovent Biologics (01801) up 5.38% and WuXi AppTec (02359) up 4.91%, while Alibaba (09988) fell 3.25%, dragging the index down by 65.17 points [2] Sector Highlights Pharmaceutical Sector - The pharmaceutical sector continued its upward trend, with notable gains from Rongchang Biologics (09995) up 12.93% and Tigermed (03347) up 8.88% [3] - The National Medical Products Administration reported that 76 innovative drugs are expected to be approved by 2025, significantly surpassing the 48 approved in 2024, with a total transaction value exceeding USD 130 billion [4] Nickel Sector - Nickel stocks showed strong performance, with Xinjiang Xinxin Mining (03833) rising 12.28% and Zhongwei New Materials (02579) up 10% [4] - Nickel prices surged over 20% in the past two weeks, driven by supply constraints from Indonesia, which plans to reduce nickel mining quotas by 2026 [4] Paper Sector - Paper stocks saw significant gains, with Nine Dragons Paper (02689) up 8.97% and Lee & Man Paper (02314) up 6.92% [5] - Several paper companies announced price increases, indicating a reduction in production pressure and a more favorable market environment [5] Coal Sector - Coal stocks generally rose, with Shougang Resources (00639) up 5.98% and China Qinfa (00866) up 5.92% [6] - The Dalian Commodity Exchange saw a surge in coal futures, and analysts expect improvements in supply-demand dynamics for the coal industry [6] Optical Communication Sector - Optical communication stocks rebounded, with Yangtze Optical Fibre (06869) rising 6.75% [6] - The sector was buoyed by strong performances in the U.S. market, particularly from Lumentum and Coherent [7] Notable Stocks - Yadea Group (01585) announced a profit increase, leading to a 4.63% rise in its stock price [8] - Jinli Permanent Magnet (300748) was active, rising 3.65% amid news of potential export restrictions on rare earth materials to Japan [9] - Jitu Express (01519) reached a new high, with a 3.39% increase, reporting significant growth in package volume [10] - GF Securities (01776) faced pressure, dropping 4.09% after announcing a share placement and convertible bond issuance to raise funds for international business development [11]

Core Viewpoint - Zhiou Technology (301376.SZ) experienced a stock price decline of 2.28%, closing at 18.01 yuan on January 7, 2023 [1] Group 1: Company Overview - Zhiou Technology was listed on the Shenzhen Stock Exchange's ChiNext board on June 21, 2023, with an initial public offering (IPO) of 40.15 million shares at a price of 24.66 yuan per share [1] - The total amount raised from the IPO was 990.099 million yuan, with a net amount of 892.0804 million yuan after expenses [1] - The actual net fundraising amount was 593.6851 million yuan less than the originally planned amount [1] Group 2: Fund Utilization - The company initially intended to raise 1.4857655 billion yuan for projects including the construction of a research and design center, expansion of the warehousing and logistics system, establishment of an operational management center in Zhengzhou, and to supplement working capital [1] - The total issuance costs for the IPO amounted to 98.0186 million yuan (excluding VAT), with underwriting fees accounting for 65.6535 million yuan [1]